Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer

BJU International

Volumn 96, Issue 4, 2005, Pages 640-646

  Corcoran, Niall M ^a   Costello, Anthony J ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b NONE

Author keywords

Chemotherapy; Lymphatic metastasis; Prostate neoplasia; Protein tyrosine kinase

Indexed keywords

IMATINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TUMOR CELL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; MALE; MICE; MICE, SCID; MODELS, ANIMAL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PIPERAZINES; PROSTATIC NEOPLASMS; PYRIMIDINES; RANDOM ALLOCATION; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 24044479372     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05699.x     Document Type: Article

References (27)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20
3. Sawyers CL. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Op General Dev 2002; 12: 111-5
4. Claesson-Welsh L. Mechanism of action of platelet-derived growth factor. Int J Biochem Cell Biol 1996; 28: 373-85
5. Uehara H, Kim SJ, Karashima T et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003; 95: 458-70
6. Corcoran NM, Najdovska M, Costello AJ. Inorganic selenium inhibits progression in an experimental model of hormone refractory prostate cancer. J Urol 2004; 171: 907-10
7. Nister M, Claesson-Welsh L, Eriksson A, Heldin C-H, Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991; 266: 16755-63
8. Pietras K, Sjoblom T, Rubin K, Heldin C-H, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3: 439-43
9. Beckmann MP, Betsholtz C, Heldin CH et al. Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains. Science 1988; 241: 1346-9
10. Yu J, Deuel TF, Kim HR. Platelet-derived growth factor (PDGF) receptor-α activates c-Jun NH2-terminal kinase-1 and antagonizes PDGF receptor-β-induced phenotypic transformation. J Biol Chem 2000; 275: 19076-82
11. Plate KH, Breier G, Farrell CL, Risau W. Platelet-derived growth factor receptor-β is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 1992; 67: 529-34
12. Sulzbacher I, Traxler M, Mosberger I, Lang S, Chott A. Platelet-derived growth factor-AA and α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol 2000; 13: 632-7
13. Shimizu A, O'Brien KP, Sjoblom T et al. The dermatofibrosarcoma protuberans-associated collagen type I α1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999; 59: 3719-23
14. Fudge K, Wang CY, Stearns ME. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor receptor α and β receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinoma. Mod Pathol 1994; 7: 549-54
15. Fudge K, Bostwick DG, Sterns ME. Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia. Prostate 1996; 29: 282-6
16. Chott A, Sun Z, Morganstern D et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999; 155: 1271-9
17. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001; 166: 2472-83
18. Sitaras NM, Sariban E, Bravo M, Pantazis P, Antoniades HN. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 1998; 48: 1930-5
19. Vlahos CJ, Kriauciunas TD, Gleason PE et al. Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells. J Cell Biochem 1993; 52: 404-13
20. Yu J, Moon A, Kim HR. Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun 2001; 282: 697-700
21. Thommes KB, Hoppe J, Vetter H et al. The synergistic effect of PDGF-AA and IGF-1 on VSMC proliferation might be explained by the differential activation of their intracellular signalling pathways. Exp Cell Res 1996; 226: 59-66
22. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 1993; 90: 393-7
23. Carroll M, Ohno-Jones S, Tamura S et al. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGF-R fusion proteins. Blood 1997; 90: 4979-52
24. Shawyer LK, Schwartz DP, Mann E et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[-4-(trifluoromethyl)-phenyl] 5-methylisoxazole-4-carboxamide. Clin Cancer Res 1997; 3: 1167-77
25. Hofer MD, Fecko A, Shen R et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004; 6: 503-12
26. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002; 297: 63-4
27. Horner A, Bord S, Kemp P, Grainger D, Compston JE. Distribution of platelet-derived growth factor (PDGF) A chain mRNA, protein, and PDGF-alpha receptor in rapidly forming human bone. Bone 1996; 19: 353-62